Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Explore this paper's citation graph
Summary
Treatment with everolimus prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma that had progressed on other targeted therapies, but were mostly mild or moderate in severity.
- Type
- article
- Published
- 2008-08-09
- Cited by
- 2,975
- References
- 23
- OpenAlex
- https://openalex.org/W18653228
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23385745
Keywords
Humanities, Philosophy
References
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
- Targeted therapy for advanced renal cell carcinoma.
- Immunotherapy for advanced renal cell cancer.
- [New guidelines to evaluate the response to treatment in solid tumors].
- Development and validation of a scale to measure disease-related symptoms of kidney cancer.
- Discrete sequential boundaries for clinical trials
- Sorafenib in advanced clear-cell renal-cell carcinoma.
- Renal-cell carcinoma--molecular pathways and therapies.
- A multiple testing procedure for clinical trials.
- TSC2 regulates VEGF through mTOR-dependent and -independent pathways.
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
- Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
- End points and United States Food and Drug Administration approval of oncology drugs.
- Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
- The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
- Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
- Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.
- Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
- Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
Cited by
- [Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
- Primary resistance to ATP-competitive mTOR inhibitors for the treatment of solid tumors
- Ligand-Directed AAVP to Deliver a Therapeutic Transgene to Neuroendocrine Tumors of the Pancreas
- Chemotherapie des Harnblasenkarzinoms
- [Management of side effects of targeted therapies in renal cancer: cutaneous side effects].
- Past, present and future of targeted therapy in solid tumors.
- Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
- Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology.
- Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial
- Nocardia brain abscess in a patient treated with everolimus for a metastatic insulinoma.
- Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
- Systemic cancer therapy: achievements and challenges that lie ahead
- Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center.
- mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes
- Pediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Temsirolimus
- Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
- Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition
- Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer
- Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Related papers
No related papers recorded.